GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
GE HealthCare (Nasdaq: GEHC) is showcasing next-generation SIGNA MR technologies at ISMRM 2026, highlighting AI-powered workflow, helium-free 1.5T systems and advanced 3T scanners. New tools such as SIGNA One, SIGNA Bolt, SIGNA Sprint with Freelium, SIGNA Studio and the investigational MAGNUS prototype aim to accelerate MR research, enhance collaboration and translate innovation into clinical practice.
GE HealthCare (Nasdaq: GEHC) reorganized operations and executive leadership effective April 29, 2026 to streamline execution, accelerate innovation, and drive growth. The company created Advanced Imaging Solutions (AIS) — a combined Imaging and Advanced Visualization Solutions segment sized at $14.6 billion — led by Phil Rackliffe.
Catherine Estrampes becomes Chief Commercial and Growth Officer to lead a new Global Markets region (all markets except China). Roland Rott will leave the company. GE HealthCare will recast financials to reflect the new segment structure in its Q2 2026 SEC filings.
GE HealthCare (Nasdaq: GEHC) reported Q1 2026 results: revenues $5.13B (+7.4% YoY; organic +2.9%), book-to-bill 1.07 and backlog $21.8B. Net income was $389M (diluted EPS $0.85); Adjusted EPS $0.99. Cash from operations $290M; free cash flow $112M. Company closed the $2.3B Intelerad acquisition and reaffirmed organic revenue guidance while reducing profit and free cash flow outlook due to inflation, tariffs and a resolved PDx supplier issue.
GE HealthCare (Nasdaq: GEHC) said members of its management team will present at two investor conferences in May and June 2026. Bank of America Health Care Conference presentation is May 12, 2026 at 10:40 am PT / 1:40 pm ET. Jefferies Global Healthcare Conference presentation is June 3, 2026 at 9:20 am ET. Webcasts will be available on the company investor website on the listed dates.
GE HealthCare (Nasdaq: GEHC) announced the first patient was dosed in the international Phase 2/3 LUMINA trial of its manganese-based MRI contrast agent, mangaciclanol, on April 23, 2026.
Mangaciclanol has FDA Fast Track designation for adults and pediatric patients aged 2+, showed tolerability in Phase 1, and demonstrates comparable relaxivity to gadobutrol. The company highlights potential supply and environmental advantages versus gadolinium agents. Mangaciclanol remains investigational and is not approved for clinical use.
GE HealthCare (Nasdaq: GEHC) expanded its collaboration with DeepHealth (RadNet subsidiary) to commercially extend DeepHealth’s AI-powered Breast Suite internationally and integrate new applications with GE’s Pristina Via mammography systems. The deal adds ProFound Pro, Safeguard Review, and cloud-first workflow tools to scale AI-enabled breast cancer screening and second‑reader workflows.
GE HealthCare (NYSE:GEHC) announced a commercial digital integration linking the bkActiv intraoperative ultrasound system with the Medtronic Stealth AXiS surgical navigation system to provide real-time imaging during cranial procedures.
The integration supports plug-and-play visualization to help assess anatomy changes such as brain shift and complements planning, navigation and robotics; the Stealth AXiS has U.S. FDA clearance for cranial procedures.
GE HealthCare (Nasdaq: GEHC) will release first quarter 2026 financial results before market open on Wednesday, April 29, 2026.
The GE HealthCare management team will host a live conference call and webcast at 8:30 a.m. ET the same day. Materials and a replay will be posted on the company investor website.
GE HealthCare (Nasdaq: GEHC) warns shareholders to reject an unsolicited mini-tender by Potemkin Limited offering up to 100,000 shares at $45.80 per share. The offer price is ~34.80% below the $70.25 closing price on March 18, 2026.
The company says the offer contains conditions, potential payment delays, and limited withdrawal rights, urges investors to obtain current market quotations, consult advisors, and take no action if they have not tendered.
GE HealthCare (Nasdaq: GEHC) will serve as the industry lead in COMPASS, a five-year, EU-funded IHI consortium with a total budget of €50.5 million and more than 60 partners to advance early detection and prediction of cardiotoxicity in cancer patients across Europe. The grant agreement was signed on March 25, 2026.
COMPASS will combine AI, advanced imaging, biomarkers and integrated care pathways to develop predictive tools, multi-omics biomarkers and an AI-powered clinical decision support pathway aimed at earlier diagnosis and coordinated cardio-oncology care.